Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing
In summary, WGS is currently more costly than SoC, however the cost can be reduced by utilizing laboratories with higher throughput and by the expected decline in cost of reagents. Our data provides guidance to decision-makers for the resource allocation needed when implementing WGS in diagnostics of hematological malignancies.
Authors
- Richard Rosenquist (ORCID: https://orcid.org/0000-0002-0211-8788)
- Thoas Fioretos (ORCID: https://orcid.org/0000-0002-3235-6154)
- Lucia Cavelier (ORCID: https://orcid.org/0009-0003-8195-370X)
- Lars‐Åke Levin (ORCID: https://orcid.org/0000-0003-2581-4863)
- Tharshini Thangavelu
- Tatjana Pandzic (ORCID: https://orcid.org/0009-0006-9032-4616)
- Anna Staffas (ORCID: https://orcid.org/0000-0001-8373-7312)
- Linda Olsson (ORCID: https://orcid.org/0000-0002-6306-6942)
- Gisela Barbany (ORCID: https://orcid.org/0000-0003-3185-2962)
- Christina Orsmark‐Pietras (ORCID: https://orcid.org/0000-0002-6533-0305)
- Valtteri Wirta (ORCID: https://orcid.org/0000-0003-3811-5439)
Institutions
- Linköping University (SE)
- Uppsala University (SE)
- National Board of Health and Welfare (SE)
- Karolinska University Hospital (SE)
- Lund University (SE)
- Science for Life Laboratory (SE)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- CS Diagnostics (DE)
- KTH Royal Institute of Technology (SE)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1080/13696998.2024.2387515
- Citations
- 10
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.85